• IMV Inc (TSX:IMV) has announced that the company will present at the 2020 BIO CEO and Investor Conference next month.
  • Management team members will give the presentation on February 10th, at the Marriott Marquis Hotel in New York.
  • A live webcast and replay of the presentation will be accessible online.
  • IMV’s share price is up 0.33 per cent, with shares trading at $6.16 apiece.

Representatives from biopharmaceutical company IMV Inc (IMV) will give a presentation at the BIO CEO and Investor Conference in February. The two-day conference will take place at the Marriott Marquis Hotel in New York City.

The occasion will bring together investors, industry analysts, and senior executives from biotechnology companies. The event is a great opportunity to let investors know about the novel class of immunotherapies which IMV is currently pioneering.

The conference will take place on February 10th and 11th, with company presentations on both days. IMV’s presentation is scheduled for Monday February 10th, at 9:30am Eastern Standard Time.

A live webcast of the presentation will be made available on the investors section of IMV’s website, under Events, Webcasts, and Presentations.

A replay will also be accessible, roughly one hour after the presentation. It will continue to be available for approximately 30 days.

IMV’s share price is up 0.33 per cent, with shares trading at $6.16 apiece.

More From The Market Online
Two people sitting across from each other with their hands folded

Safety Strips’ U.S. expansion in partnership with Greenlane Holdings

Safe Supply is committed to transforming healthcare through innovative medical technologies and AI-powered solutions.
Rexall drug store in Toronto.

McKesson to sell Rexall and Well.ca to private equity firm

McKesson (NYSE:MCK), a diversified healthcare stock, will sell its Rexall and Well.ca businesses to Birch Hill Equity Partners.
MindBio Therapeutics chief executive officer Justin Hanka.

MindBio advances world-first psychedelic microdosing clinical trials

MindBio Therapeutics (CSE:MBIO) announces the successful completion of its Phase 1 and 2a clinical trials on depression treatment.
Psilocybin mushrooms

Optimi will test its psilocybin on frontline healthcare workers

Health Canada clears psychedelics stock Optimi Health (CSE:OPTI) to test its psilocybin on frontline healthcare workers.